Cargando…

Morbidity Control of Schistosomiasis by Mass Drug Administration: How Can We Do It Best and What Will It Take to Move on to Elimination?

The World Health Organization (WHO) has, for some time, encouraged countries endemic for schistosomiasis to control morbidity from this disease through mass drug administration (MDA) of the well-tolerated drug, praziquantel (PZQ). With the London Declaration in January 2012 and the promise by Merck...

Descripción completa

Detalles Bibliográficos
Autor principal:	Colley, Daniel G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Tropical Medicine 2014
Materias:	Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204048/ https://www.ncbi.nlm.nih.gov/pubmed/25425948 http://dx.doi.org/10.2149/tmh.2014-S04

Ejemplares similares

When Should the Emphasis on Schistosomiasis Control Move to Elimination?
por: Secor, W. Evan, et al.
Publicado: (2018)

The evolving schistosomiasis agenda 2007-2017—Why we are moving beyond morbidity control toward elimination of transmission
por: King, Charles H.
Publicado: (2017)

The best pharmaceuticals for children—what can we do?
por: Li, Hao, et al.
Publicado: (2020)

How we remember what we can do
por: Declerck, Gunnar
Publicado: (2015)

Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?
por: Wang, Shuncong, et al.
Publicado: (2020)

Doing what we do best, only better
por: Nunnari, Jodi, et al.
Publicado: (2016)

Drugs for malaria elimination: what do we have now and what do we need?
por: Shanks, Dennis
Publicado: (2014)

Surveillance of bloodstream infections in pediatric cancer centers – what have we learned and how do we move on?
por: Simon, Arne, et al.
Publicado: (2016)

Molecular Techniques as Alternatives of Diagnostic Tools in China as Schistosomiasis Moving towards Elimination
por: Lv, Chao, et al.
Publicado: (2022)

One Year on: An Overview of Singapore’s Response to COVID-19—What We Did, How We Fared, How We Can Move Forward
por: Anand, S Vivek, et al.
Publicado: (2021)

Control and Elimination of Schistosomiasis as a Public Health Problem: Thresholds Fail to Differentiate Schistosomiasis Morbidity Prevalence in Children
por: Wiegand, Ryan E, et al.
Publicado: (2021)

Malaria: How Are We Doing and How Can We Do Better?
por: Rosenthal, Philip J., et al.
Publicado: (2019)

How Do We Best Diagnose Malaria in Africa?
por: Rosenthal, Philip J.
Publicado: (2012)

Paediatric schistosomiasis: What we know and what we need to know
por: Osakunor, Derick N. M., et al.
Publicado: (2018)

Recurring Cystitis: How Can We Do Our Best to Help Patients Help Themselves?
por: Ben Hadj Messaoud, Sarah, et al.
Publicado: (2022)

What do hotels and hospitals have in common? How we can learn from the hotel industry to take better care of patients
por: Zygourakis, Corinna C., et al.
Publicado: (2014)

Assessment practices in undergraduate clinical medicine training: What do we do and how can we improve?
por: Brits, Hanneke, et al.
Publicado: (2020)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

How Do We Move Forward With Trauma-Informed Care?
por: Schimmels, JoEllen, et al.
Publicado: (2021)

How Can We Use the Promoting Action on Research in Health Services (PARIHS) Framework to Move from What We Know to What We Should Do for the Rehabilitation of a Painful Hemiplegic Shoulder (PHS)?
por: Alatawi, Salem F
Publicado: (2022)

Schistosomiasis vaccines: where do we stand?
por: Tebeje, Biniam Mathewos, et al.
Publicado: (2016)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

What Can We Do to Be Saved?
por: Visanska, Samuel A.
Publicado: (1913)

Globalization of spine care: how are we doing and what are we doing?
por: Chapman, Jens
Publicado: (2012)

Willful: how we choose what we do
por: Robb, Richard
Publicado: (2019)

Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies
por: Tchuem Tchuenté, Louis-Albert, et al.
Publicado: (2017)

Mental health among clinicians: what do we know and what can we do?
por: Patel, Mittal, et al.
Publicado: (2021)

Injection protection: are we taking it seriously, how can we make it safer?
por: Kain, V, et al.
Publicado: (2010)

How Can We Best Measure Frailty in Cardiosurgical Patients?
por: Laux, Magdalena L., et al.
Publicado: (2023)

Cancer in Croatia; where do we stand and how to move forward?
por: Vrdoljak, Eduard
Publicado: (2012)

COVID-19; beyond the obvious: how do we move forward?
por: Nasoodi, Afshin, et al.
Publicado: (2020)

The state of health research governance in Africa: what do we know and how can we improve?
por: Nabyonga-Orem, Juliet, et al.
Publicado: (2021)

Phytochemical Molluscicides and Schistosomiasis: What We Know and What We Still Need to Learn
por: Augusto, Ronaldo de Carvalho, et al.
Publicado: (2018)

In memoriam: Susan Abmayr (1956–2019) – “What do we do? Whatever it takes!”
por: Geisbrecht, Erika R., et al.
Publicado: (2019)

What can we do about osteoarthritis?
por: Lohmander, L Stefan
Publicado: (2000)

Late presenters: what can we do?
por: Mussini, C
Publicado: (2012)

Why do many pheasants released in the UK die, and how can we best reduce their natural mortality?
por: Madden, Joah R., et al.
Publicado: (2018)

Chronic Kidney Disease—How Does It Go, and What Can We Do and Expect?
por: Chang, Li-Yun, et al.
Publicado: (2023)

Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?
por: Abdulameer, Shaymaa Abdalwahed, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fpk2lurbthev17cuups9pe0quh